At Axion BioSystems, our goal is to help you “explore life’s circuitry”—the intricate, electrically-active behavior of our cells. Our innovative and award-winning products are designed to help you investigate the function of cells from the heart, brain and more with an easy-to-use, in vitro assay.
After launching the first commercial multi-well MEA system, the Maestro™, we’ve continued to expand on the promise of this technology with a steady pipeline of innovative, industry-leading products that increase throughput, functionality and information drawn from MEA assays.
Our commitment to your discoveries also includes expert knowledge of the biological applications our technology enables. We are a trusted scientific partner in many research collaborations and hope you’ll reach out to us to discuss how Axion’s MEA platform can advance your journey to learn more about life’s circuitry.
Tom O’Brien was most recently a senior executive at Philips Medical Systems, a division of Royal Philips, after the sale of Intermagnetics General Corporation (NASDAQ: IMGC). At Intermagnetics, he held the role of Executive Vice President, Corporate Development and President, Invivo Medical Devices. Prior to that, he has held various senior executive positions in both public and private companies, in the U.S. and abroad. Tom holds a Bachelor’s Degree with highest honors in Industrial Engineering from Georgia Tech and an MBA from the University of Chicago.
Jim Ross was previously a product development engineer for Advanced Micro Devices and the co-founder of Nanogrip Technologies, maker of micro-scale devices used to manipulate MEMs components. He has over a decade of experience in MEMS fabrication, analog circuit design, and neural interfacing technology. During his tenure at the Microelectronics Research Center and the Laboratory for Neuroengineering, he was instrumental in producing over a dozen critically enabling technologies for the manipulation and sensing of neural tissue (many of which are patent pending). Jim received a Bachelor of Science degree in Electrical Engineering from Louisiana State University and a Doctorate in Biomedical Engineering from Georgia Tech.
Glenn Epstein, Chairman
Glenn Epstein was most recently Chairman and CEO of Intermagnetics General Corporation (NASDAQ: IMGC). He began his career as an engineer at General Electric before moving to the U.K. to take on progressive management roles with Oxford Instruments plc. Glenn joined Intermagnetics in 1997 as President and COO, took over as CEO in 1999 and was elected Chairman in 2002. He led the company through multiple years of high growth until negotiating the sale of Intermagnetics to Royal Philips for $1.3 billion. Currently, Glenn serves on the boards of Fuel Cell Energy (NASDAQ:FCEL) and X-Ray Optical Systems. He received a BS in Mechanical Engineering from the University of Vermont.
David Gibson, Board Member
David Gibson was President and CEO of XOS, an analytical-instrument company. David founded XOS (X-Ray Optical Systems) in 1991. After leading the company through a phase of basic research followed by multiple years of high growth, he negotiated the sale to Danaher in 2011. Subsequent to the merger he was President and Chief Growth Officer for XOS as a Danaher subsidiary. Prior to XOS, David was an U.S. Army Infantry officer, sales and marketing manager at Corning, and consultant and engagement manager at McKinsey. He received Bachelor of Science degrees in Mechanical Engineering and in Economics from MIT and an MBA from the Sloan School at MIT.
Michelle Jarrard, Board Member
Michelle Jarrard is the Managing Director for the GRA Venture Fund, LLC, a private investment fund providing early-stage capital to Georgia based technology companies. She oversees the Fund’s investment decisions and performance. Prior to joining the Fund, Michelle was a Senior Partner at McKinsey & Company. She served as the firm’s Global Chief HR and Talent Officer. She is currently on the Board of Trustees for Children’s Healthcare of Atlanta and a Trustee of the Georgia Tech Foundation. Michelle earned her MBA from Harvard Business School and a Bachelor’s Degree in Industrial Engineering from Georgia Institute of Technology, with highest honors.
Jay Teich, Board Member
Jay Teich, founder and CEO of Seahorse Bioscience, led the development and commercialization of instruments that enable scientists to study metabolism in living cells. In collaboration with top academic and industry leaders, Seahorse added a new dimension to the study of cellular function while creating a robust new market. In 2015, Agilent Technologies acquired Seahorse for $243MM. Prior to Seahorse, Jay led a management buyout of Inframetrics Corp, technology leaders in thermal imaging cameras. Following a period of rapid growth, Jay merged the company with FLIR Corporation to form the world’s largest thermal imaging company now over $1 billion in sales. Jay is an Electrical Engineering graduate of Lehigh University.
Jim Filippini | Vice President, Global Sales
David Stahl | Director, Software Development
Rob Grier | Director, Operations
Amanda Preyer, PhD | Hardware Manager
Andy Heckerling | Manager, Advanced Development and Technical Operations
Daniel Millard, PhD | Applications Director
Isaac Clements, PhD | Principal Engineer
Mike Clements, PhD | Scientific Director
Robert Selby | Accounting Manager
Launch your career in one of the fastest growing and emerging life science fields.